NEIL KUMAR - 19 Mar 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BBIO	Stock Option (Right to Buy)	Award	$0	+71,208		$0.000000	71,208	19 Mar 2025	Common Stock	71,208	$33.75	Direct	F1
transaction	BBIO	Restricted Stock Units	Award	$0	+184,860		$0.000000	184,860	19 Mar 2025	Common Stock	184,860		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	1/16th of the shares subject to this option vest and become exercisable on May 16, 2025, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
F2	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3	The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2025, and thereafter, 1/16th of the underlying shares will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.